Inhalable Nanoparticle Therapy Shows Promise for Treating Tuberculosis
A fresh inhalable treatment for tuberculosis (TB) is under development at the University at Buffalo, offering a potential solution to the challenges of traditional TB therapy. Researchers have engineered a nanoparticle system designed to deliver the key TB drug rifampin directly to the lungs, potentially reducing side effects and improving treatment adherence.
The Challenge of Traditional TB Treatment
Tuberculosis remains one of the world’s deadliest infectious diseases, despite being curable. Current treatment regimens involve months of multiple drugs, often causing significant side effects. These factors contribute to patients struggling to complete treatment, leading to treatment failure and the emergence of drug-resistant TB strains .
How the New Therapy Works
The research team, led by Jessica L. Reynolds, PhD, associate professor of medicine at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, developed a biocompatible nanoparticle system to encapsulate rifampin. These nanoparticles are designed to be inhaled, delivering the drug directly to the lungs, where TB bacteria reside .
According to Hilliard L. Kutscher, PhD, research assistant professor of medicine and the study’s first author, the nanoparticles contain a biodegradable core loaded with rifampin. The outer layer is designed to attach to macrophages, immune cells that TB bacteria infect, and stimulate immune activity .
“These particles are specially built to go straight to the lungs and be taken up by lung immune cells called macrophages, which are where TB bacteria hide,” Kutscher explains. “They are designed to slowly release rifampin over time, to stimulate the immune system to better fight TB and to reduce drug exposure to the rest of the body, lowering side effects.”
Study Findings
The study, published in Antimicrobial Agents and Chemotherapy, demonstrated that the inhaled nanoparticle treatment delivered rifampin more effectively to the lungs compared to oral administration. In mouse models of TB, the inhaled nanoparticles maintained higher drug levels in the lungs for up to a week after a single dose .
The research team evaluated the approach in two mouse models of TB, one representing a general lung infection and another mimicking severe human TB lung damage. Results showed the inhaled nanoparticle therapy effectively reduced Mycobacterium tuberculosis in both models .
Potential Benefits and Future Directions
The researchers suggest that this approach could lead to less frequent dosing, potentially reducing treatment from daily to weekly administration. This could improve patient adherence, lower side effects, and increase accessibility to TB care worldwide .
Further research will focus on combining the nanoparticle system with other TB antibiotics to create combination therapies, which remain the cornerstone of TB treatment .
Beyond Tuberculosis: Expanding Applications
The potential benefits of this technology extend beyond TB. Rifampin is also used to treat other serious lung infections caused by non-tuberculous mycobacteria. The targeted lung delivery system could also address drug interactions that limit rifampin’s use in treating other lung diseases .
Patrick O. Kenney, MD, clinical assistant professor of pediatrics and co-author of the study, notes that delivering rifampin directly to the lungs could minimize its impact on liver enzymes, reducing interference with other antibiotics and allowing for more effective treatment of complex lung infections .
All experiments involving Mycobacterium tuberculosis were performed in a certified Biosafety Level 3 (BSL-3) laboratory, adhering to strict safety regulations .